Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 6;14(23):6007.
doi: 10.3390/cancers14236007.

The Reporting, Use, and Validity of Patient-Reported Outcomes in Multiple Myeloma in Clinical Trials: A Systematic Literature Review

Sam Salek  1 , Tatiana Ionova  2 , Esther Natalie Oliva  3 , Marike Andreas  4 , Nicole Skoetz  4 , Nina Kreuzberger  4 , Edward Laane  5   6
Affiliations
Review

The Reporting, Use, and Validity of Patient-Reported Outcomes in Multiple Myeloma in Clinical Trials: A Systematic Literature Review

Sam Salek et al. Cancers (Basel). .

Abstract

Background: Patient-reported outcomes (PROs) are becoming increasingly important in supporting clinical outcomes in clinical trials. In multiple myeloma (MM), PRO measurement is useful to reveal how treatment affects physical, psychosocial, and functional behaviour as well as symptoms and treatment-related adverse events to evaluate the benefit-risk ratio of a particular drug or drug combination. We report the types of PRO instruments used in MM, the frequency in which they are utilised in randomised controlled trials (RCTs), and the consistency of their reporting.

Methods: The European Hematology Association (EHA) supports the development of guidelines for the use of PROs in adult patients with haematological malignancies. The first step is the present systematic review of the literature. MEDLINE and CENTRAL were searched for RCTs in MM between 2015 and 2020. Study design, characteristics of MM and its treatment, the primary outcomes, and the types of PRO instrument(s) were extracted using a predefined template. Additionally, in a stepwise approach, it was assessed whether the identified instruments had been validated for multiple myeloma patients, patients with haematological malignancies, or cancer patients.

Results: Following screening for RCTs, 283 studies were included for review from 10,707 records retrieved, and 118 of these planned the use of PRO measures. Thirty-eight PRO instruments were reported. The most frequently used instrument (92 studies) was the EORTC QLQ-30. The EORTC-MY20 MM-specific questionnaire was the second most frequently used (50 studies), together with the EQ-5D (50 studies). Only 19 PRO instruments reported were consistent with the trial registry. Furthermore, in 58 publications, the information on PRO instruments differed between the publication and the trial registry. Further, information on PRO in HTA reports was available for 26 studies, of which 18 reports were consistent with the trial registries. Out of the 38 instruments used, six had been validated for patients with multiple myeloma (the most frequently used), six for patients with haematological malignancies, and 10 for cancer patients in general.

Conclusions: The findings indicate that the measurement of PROs in RCTs for MM is underutilised, underreported, and often inconsistent. Guidelines for the appropriate use of PROs in MM are needed to ensure standardisation in selection and reporting. Furthermore, not all PRO instruments identified have been validated for myeloma patients or patients with haematological malignancies. Thus, guidelines for the appropriate use and reporting of PROs are needed in MM to ensure standardisation in the selection and reporting of PROs.

Keywords: clinical trials; multiple myeloma; patient-reported outcomes; quality of life; symptoms; systematic review; validation studies.

PubMed Disclaimer

Conflict of interest statement

S.S. has received an honorarium for providing consultancy to NovoNordisk and Abbvie and is a copyright holder of several instruments, including FROM-16, MLCDP, T-QoL, HidroQoL, PDF, RQLP, and the HM-PRO. E.N.O. has received an honorarium for providing consultancy and participating in speakers’ panels for AbbVie, Alexion, Amgen, Janssen, Daiichi, and Novartis. She is a copyright holder of the QOL-E instrument and the HM-PRO. T.I. is the Principal Investigator of sponsor-initiated observational studies for Amgen and Takeda, has received an honorarium for participating in speakers’ panels for BMS, Amgen, and Novartis and is a copyright holder of the HM-PRO. E.L., N.S., N.K., M.A.: none known.

Figures

Figure 1
Figure 1
PRISMA flow diagram.
Figure 2
Figure 2
The prevalence of PRO instruments used in MM RCTs according to the SLR.
Figure 3
Figure 3
Consistency of reporting PRO instruments in MM RCTs.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Callander N.S., Baljevic M., Adekola K., Anderson L.D., Campagnaro E., Castillo J.J., Costello C., Devarakonda S., Elsedawy N., Faiman M., et al. NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022. J. Natl. Compr. Cancer Netw. 2022;20:8–19. doi: 10.6004/jnccn.2022.0002. - DOI - PubMed
    1. Dimopoulos M.A., Moreau P., Terpos E., Mateos M.V., Zweegman S., Cook G., Delforge M., Hájek R., Schjesvold F., Cavo M., et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(†) Ann. Oncol. 2021;32:309–322. doi: 10.1016/j.annonc.2020.11.014. Erratum in Ann. Oncol. 2021, 5, e528. - DOI - PubMed
    1. Cowan A.J., Green D.J., Kwok M., Lee S., Coffey D.G., Holmberg L.A., Tuazon S., Gopal A.K., Libby E.N. Diagnosis and Management of Multiple Myeloma: A Review. JAMA. 2022;327:464–477. doi: 10.1001/jama.2022.0003. - DOI - PubMed
    1. Van Valckenborgh E., Schouppe E., Movahedi K., De Bruyne E., Menu E., De Baetselier P., Vanderkerken K., Van Ginderachter J.A. Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow. Leukemia. 2012;26:2424–2428. doi: 10.1038/leu.2012.113. - DOI - PubMed
    1. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer Statistics, 2021. Ca Cancer J. Clin. 2021;71:7–33. doi: 10.3322/caac.21654. - DOI - PubMed

LinkOut - more resources